Anixa Biosciences Inc (ANIX) 股利

Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology. The company is headquartered in San Jose, California and currently employs 4 full-time employees. The firm's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The firm's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. The firm is engaged in the development of vaccines for the treatment or prevention of triple negative breast cancer and other breast cancers which express the a-lactalbumin protein. Its vaccine technologies are focused on immunizing against retired proteins that have been found to be expressed in certain forms of cancer.